Semaglutide

What it is

Semaglutide is a GLP-1 (Glucagon-Like Peptide-1) receptor agonist. It is a synthetic version of a hormone your body naturally produces in the gut after you eat. While it was originally developed to help people with Type 2 diabetes manage their blood sugar, it gained worldwide fame when researchers realized it could also lead to significant weight loss.

Approved by the FDA under brand names like Ozempic and Wegovy, Semaglutide is unique because it is designed to last a long time in the body. While the natural hormone disappears within minutes, this peptide is modified to circulate for about a week, allowing for once-weekly administration.

What it does

Semaglutide works in three main ways. First, it tells your pancreas to release insulin when blood sugar is high. Second, it slows down "gastric emptying," which means food stays in your stomach longer, making you feel full sooner. Third, and perhaps most importantly, it communicates with the brain's "reward center" to reduce food cravings and the "food noise" that often leads to overeating.

Users report that it feels like a "switch" being flipped, making it much easier to stick to a healthy diet. Beyond weight loss, research has shown it can significantly reduce the risk of major cardiovascular events like heart attacks and strokes in people with obesity or heart disease.

What the evidence says

The evidence for Semaglutide is exceptionally strong, backed by massive clinical trials (the STEP and SUSTAIN trials) involving tens of thousands of participants. In these studies, participants using the highest dose lost an average of 15% of their body weight over 68 weeks—far higher than what is typically seen with older weight-loss medications.

We have years of data confirming its safety and efficacy for both diabetes and obesity. However, we also know that the benefits tend to plateau after a year or two, and many users find that if they stop the medication without making permanent lifestyle changes, the weight can return.

What it costs

For those without insurance coverage, Semaglutide is expensive. The retail price for brand-name Ozempic or Wegovy in the US is often between $900 and $1,300 per month. Some users access it through compounding pharmacies at a lower price point ($200 to $500), though as of 2026 this landscape has tightened significantly: the FDA's enforcement discretion for 503A/503B compounding ended in 2025, and compounded versions face increasing regulatory scrutiny.

Side effects and risks

The most common side effects are gastrointestinal: nausea, vomiting, diarrhea, and constipation. Most users find these symptoms are worst when first starting or increasing the dose. There are also rarer but more serious risks, including pancreatitis, gallbladder issues, and a potential link to a specific type of thyroid cancer (medullary thyroid carcinoma) seen in animal studies.

Recent user reports have flagged additional symptoms—menstrual irregularities, "Ozempic face" volume loss, muscle loss with rapid weight reduction—that researchers are actively investigating as of 2026.

Where users source it

Semaglutide is a prescription-only medication. We strongly advise obtaining it through a licensed healthcare provider and a legitimate pharmacy. While "research grade" versions exist online, the high risk of counterfeits and the precision required for metabolic dosing make professional medical supervision essential.

Sources

• Wilding JP, et al. (2021). "Once-Weekly Semaglutide in Adults with Overweight or Obesity." NEJM. PMID 33567185
• Lincoff AM, et al. (2023). "Semaglutide and Cardiovascular Outcomes in Patients with Overweight or Obesity." NEJM. PMID 37952131
• FDA. (April 2026). "FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize."
• Pharmacy Times. (March 2026). "FDA and Novo Nordisk warned of GLP-1 telehealth compounding."